ERBB2 and breast cancer: The incidence of PIK3CA mutations, the activation of PI3K/Akt/mTOR signaling axis, and, in correlation with these, the increased mTORC2 activity (p-Ser473-Akt)–related HER2 expression were found to be involved in the liver metastases of breast cancers, which are occurring more frequently [336].